Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia-Reference-Cited by-同舟云学术

Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia

Published:2011-05-03 Issue:8 Volume:25 Page:1365-1368
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Blink M,Buitenkamp T D,van den Heuvel-Eibrink M M,Danen-van Oorschot A A,de Haas V,Reinhardt D,Klusmann J-H,Zimmermann M,Devidas M,Carroll A J,Basso G,Pession A,Hasle H,Pieters R,Rabin K R,Izraeli S,Zwaan C M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201186.pdf

Reference9 articles.

1. Hasle H . Pattern of malignant disorders in individuals with Down′s syndrome. Lancet Oncol 2001; 2: 429–436.

2. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M . AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355–1360.

3. Hitzler JK, Zipursky A . Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11–20.

4. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005; 106: 4043–4049.

5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute lymphoblastic leukaemia;Nature Reviews Disease Primers;2024-06-13

2. The paradox of Myeloid Leukemia associated with Down syndrome;Biochemical Pharmacology;2022-07

3. Phenotypes Associated with Down Syndrome and Causative Genes;Down Syndrome and Other Chromosome Abnormalities;2022-03-23

4. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP‐binding site of the kinase of JAK3;Journal of Cellular and Molecular Medicine;2020-06-17

5. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models;Blood Advances;2018-07-09